Original contributionPhysical and chemical properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil
References (51)
Surface properties of superparamagnetic iron oxide MR contrast agents
Magn. Reson. Imaging
(1995)- et al.
Particle size, particle size distribution, and related measurements of supported metal catalysts
Catal. Rev. Sci. Eng.
(1987) - et al.
Spectral and other physicochemical properties of submicron powders of hematite (α-Fe2O3), maghemite (γ-Fe2O3), magnetite (Fe3O4), goethite (α-FeOOH), and lepidocrocite (γ-FeOOH)
J. Geophys. Res.
(1985) - et al.
Use of magnetite particles as a contrast agent for MR imaging of the liver
Radiology
(1990) - et al.
Iron oxide-enhanced MR imaging of the liver and spleen: Review of the first 5 years
AJR
(1990) - et al.
Contrast-enhanced MR imaging of the liver
JMRI
(1994) Gastrointestinal contrast agents
AJR
(1991)- et al.
Phase I clinical evaluation of a new iron oxide MR contrast agent
J. Magn. Reson. Imaging
(1994) - et al.
MR lymphography: Study of a high-efficiency lymphotrophic agent
Radiology
(1994) - et al.
Biologically degradable superparamagnetic materials for use in clinical applications
(1989 May 9)
Synthesis of polysaccharide covered superparamagnetic oxide colloids
Magnetic particles for use in separations
Iron in drugs, spectrophotometric method, final action
Iron in drugs, spectrophotometric method, final action
JAOAC
Iron oxides and oxyhydroxides
Particle sizes and their statistics from Debye-Scherrer lines
The measurement of catalyst dispersion
Particle size analysis in ferrofluids
J. Magnetism Magn. Mater.
Cited by (614)
Study of the suitability of manganese-substituted cobalt ferrites nanoparticles as MRI contrast agent and treatment by employing hyperthermia temperature
2022, Journal of Magnetism and Magnetic MaterialsNanoarchitectured manganese dioxide (MnO<inf>2</inf>)-based assemblies for biomedicine
2022, Coordination Chemistry ReviewsComplement opsonization of nanoparticles: Differences between humans and preclinical species
2021, Journal of Controlled ReleaseOne-pot synthesis of carboxymethyl-dextran coated iron oxide nanoparticles (CION) for preclinical fMRI and MRA applications
2021, NeuroImageCitation Excerpt :In addition, GDCA have been associated with long-term toxicity in the kidneys and brain (Gulani et al., 2017; Kuo et al., 2007; Malayeri et al., 2016; Wei et al., 2017). Development of MRI contrast agents based on superparmagnetic iron-oxide nanoparticles (SPIO, mean hydrodynamic diameter > 50 nm) or ultrasmall superparamagnetic iron-oxide nanoparticles (USPIO, mean hydrodynamic diameter ≤ 50 nm) have been increasingly used for diagnostic and theranostic purposes (Atanasijevic and Jasanoff, 2007; Atanasijevic et al., 2006; Chen et al., 2014, 2015; Himmelreich et al., 2005; Jung and Jacobs, 1995; Jung et al., 2014; Senpan et al., 2009; Shapiro et al., 2005, 2004; Stark et al., 1988; Wei et al., 2017; Weissleder et al., 1990a, 1990b; Wu et al., 2004). Careful manipulation of synthesis variables such as the size, magnetization and surface properties of SPIO/USPIO can be easily tailored to achieve longer intravascular half-life, higher MR sensitivity and better biocompatibility, as compared to commercially available GDCA.
A novel amino phosphonate-coated magnetic nanoparticle as MRI contrast agent
2021, Applied Surface Science